Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes

BackgroundRecently, network meta-analysis of survival data with a multidimensional treatment effect was introduced. With these models the hazard ratio is not assumed to be constant over time, thereby reducing the possibility of violating transitivity in indirect comparisons. However, bias is still present if there are systematic differences in treatment effect modifiers across comparisons.MethodsIn this paper we present multidimensional network meta-analysis models for time-to-event data that are extended with covariates to explain heterogeneity and adjust for confounding bias in the synthesis of evidence networks of randomized controlled trials. The impact of a covariate on the treatment effect can be assumed to be treatment specific or constant for all treatments compared.ResultsAn illustrative example analysis is presented for a network of randomized controlled trials evaluating different interventions for advanced melanoma. Incorporating a covariate related to the study date resulted in different estimates for the hazard ratios over time than an analysis without this covariate, indicating the importance of adjusting for changes in contextual factors over time.ConclusionAdding treatment-by-covariate interactions to multidimensional network meta-analysis models for published survival curves can be worthwhile to explain systematic differences across comparisons, thereby reducing inconsistencies and bias. An additional advantage is that heterogeneity in treatment effects can be explored.

[1]  G. Lu,et al.  Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .

[2]  Paul Landais,et al.  Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. , 2004, Journal of clinical epidemiology.

[3]  J. Dunn,et al.  Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma , 2001 .

[4]  A. Brennan,et al.  PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS , 2007 .

[5]  M. Atkins,et al.  Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Lumley Network meta‐analysis for indirect treatment comparisons , 2002, Statistics in medicine.

[7]  N. G. Best,et al.  WinBUGS User Manual: Version 1.4 , 2001 .

[8]  P. Queirolo,et al.  Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Alex J. Sutton,et al.  Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment , 2011 .

[10]  A E Ades,et al.  Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies , 2010, Research Synthesis Methods.

[11]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[12]  J. Dunn,et al.  Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  A. Paccagnella,et al.  Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients , 2001, Melanoma research.

[14]  Joseph C Cappelleri,et al.  Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  C. Falkson,et al.  Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Deborah M Caldwell,et al.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.

[17]  Arthur P. Dempster,et al.  The direct use of likelihood for significance testing , 1997, Stat. Comput..

[18]  P. Hersey,et al.  Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. , 1993, Melanoma research.

[19]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  Jeroen P. Jansen,et al.  Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes , 2012 .

[21]  Georgia Salanti,et al.  Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. , 2012, Journal of clinical epidemiology.

[22]  N. Welton,et al.  Addressing between‐study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non‐rheumatic atrial fibrillation , 2009, Statistics in medicine.

[23]  David C Hoaglin,et al.  Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  Julian P T Higgins,et al.  A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. , 2009, Journal of clinical epidemiology.

[25]  M. Weichenthal,et al.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Z. Philips,et al.  Network meta‐analysis of parametric survival curves , 2010, Research synthesis methods.

[27]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[29]  Nicky J Welton,et al.  Evaluating novel agent effects in multiple‐treatments meta‐regression , 2010, Statistics in medicine.

[30]  C. Begg,et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[32]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[33]  J. Jansen Network meta-analysis of survival data with fractional polynomials , 2011, BMC medical research methodology.

[34]  C. Boni,et al.  Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. , 1992, The New England journal of medicine.

[35]  Jeroen P Jansen,et al.  Network meta‐analysis of individual and aggregate level data , 2012, Research synthesis methods.